Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

56 results about "Antimalarial Agent" patented technology

A pharmaceutical agent that cures or prevents malaria. Certain anti-malarials, specifically chloroquine derivatives, have been used in the treatment of autoimmune disease.

[(10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde semicarbazones (sulfur) series substances as well as preparation method and application thereof

InactiveCN102010420AOrganic active ingredientsAntimycoticsArtemisininsBenzaldehyde semicarbazone
The invention relates to [(10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde semicarbazones (sulfur) series substances and provides a structure, a preparation method and application of a novel artemisinine 10-locus derivative. The structural formula of the [(10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde semicarbazones (sulfur) series substance is shown in a formula I. The invention also relates to pharmaceutically-acceptable slats, a solvate, an optical isomer or a polymorphic substance of the [(10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde semicarbazones (sulfur) series substances and a medicinal composition by taking the compounds as active components. As novel antimalarial agents, anti-tumor agents and antifungal agents, the compounds can be used for treating or preventing malaria, mycotic infection, malignant tumor and the like. The compounds can be prepared by reacting dihydroartemisinine as an initial raw material with trifluoroacetic anhydride/triethylamine to obtain 10(R)-trifluoro-acetoxyl-9,10-dihydroartemisinine, directly reacting the 10(R)-trifluoro-acetoxyl-9,10-dihydroartemisinine with hydroxy benzaldehyde without separation to obtain (10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde, and reacting the (10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde with the substituted amino (sulfur) urea compounds in acid catalysts and alcohol solvents to obtain target compounds.
Owner:SHENYANG PHARMA UNIVERSITY

Combination kit used in the treatment of malaria

A combination kit for the treatment of malaria caused by Plasmodium vivax (P. vivax) having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.
Owner:NICHOLAS PIRAMAL INDIA LTD +1

Preparation of substituted indole lactam derivative and application of substituted indole lactam derivative as antimalarial agent

The invention designs an efficient synthesis method for preparing a compound shown as a general formula (I) and an application of a derivative of the compound to the research and development of an antimalarial active medicament. The method comprises the following steps of: dissolving a reactant into an appropriate solvent; and reacting under the irradiation condition of a high-voltage mercury lamp (ultraviolet lamp). In the method disclosed by the invention, a series of poly-substituted indole lactam compounds taking 3,4,5-trisubstituted indole as a basic framework are efficiently synthesized with a one-pot method under an illumination condition, so that the defects of complex steps, difficulty in operating and low total yield existing in synthesis of the type of compounds under the condition of the prior art are overcome. Derivatives containing different substituted functional groups are obtained only through a four-step reaction, and the type of compounds has potential antimalarial activity, so that necessary material bases are provided for the researches of active screening, acting mechanisms and structure-activity relationships of a large quantity of analogues, and the type of compound can possibly become a new type of antimalarial candidate medicament. The general formula (I) is shown in the specifications.
Owner:PEKING UNIV

Process for isolating artemisinin from artemisia annua

InactiveUS20030185914A1Simple and rapid and cost-effective and practicalOrganic active ingredientsBiocideArtemisia annuaBiology
The present invention relates to a process for the isolation of artemisinin, an antimalarial agent from the herb of the Artemisia annua plant, comprising of extracting the herb with ethanol, partitioning of the extract between water and hexane, followed by evaporative crystallization of artemisinin from hexane phase to produce substantially pure artemisinin.
Owner:COUNCIL OF SCI & IND RES

Tetrahydroisoquinolines as antimalarial agents

The invention relates to novel tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
Owner:AISSAOUI HAMED +3

Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents

ActiveUS6979740B2Low toxicityReduced methemoglobin toxic side effectBiocideOrganic chemistryResistant strainMalaria
The present invention is concerned with the development of novel 8-aminoquinoline analogs in the treatment and prevention of malaria and the said compound has broad spectrum of activity against the blood as well as tissue stages of the human malaria parasites makes these compounds very attractive in the cure and prevention of malaria caused by drug-sensitive and multidrug resistant strains and also it is expected that development of these compounds as ideal antimalarial agents may lead to suppression as well as radical cure of the malaria infection with single drug therapy.
Owner:NAT INST OF PHARMA EDUCATION & RES DEPT OF PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products